D-0185-2021 Class II Terminated

Recalled by Ascend Laboratories LLC — Parsippany, NJ

FDA drug recall D-0185-2021 was initiated by Ascend Laboratories LLC on Nov 23, 2020 and is designated Class II. Reason for recall: Failed Impurity/Degradation Specifications: Unidentified impurities not complying with specifications were observed in various lots of Cephalexin FOS USP 125 mg/5 mL. The recall status is terminated (terminated Jun 1, 2023). Affected quantity: 20,232 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 13, 2021
Initiation Date
Nov 23, 2020
Termination Date
Jun 1, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
20,232 bottles

Product description

Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, packaged as a) 100 ml (when mixed) bottle, NDC 67877-544-88; b) 200 ml (when mixed) bottle NDC 67877-544-68, Rx Only, Manufactured by: Alkem Laboratories, Ltd, Mumbai -400 013 INDIA. Distributed by: Ascend Lab,oratories, LLC Parsippany, NJ 07054

Reason for recall

Failed Impurity/Degradation Specifications: Unidentified impurities not complying with specifications were observed in various lots of Cephalexin FOS USP 125 mg/5 mL.

Distribution pattern

Distributed Nationwide in the USA

Code information

Lot#: a) 19144340, 19144341, Exp AUG 2021; b) 20142226, 20142227, Exp MAY 2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0185-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0185-2021. Report a data issue: hello@regdatalab.com.